Romiplostim  别名：Romiplate; AMG531; 罗米司亭

Romiplostim（Romiplate、罗米司亭）是一种Thrombopoietin(TPO)受体激动剂（TPO-RA），能与巨核细胞前体上的TPO受体结合并激活，进而导致血小板生成增加。

Romiplostim 用于小鼠动物实验配置方法、给药方式、剂量参考：

1) Administration of ARS Protective/Mitigative Agents

The thrombopoietin receptor agonist romiplostim (RP), as an acute radiation syndrome (ARS) mitigator, was intraperitoneally administered once daily for 3 consecutive days to irradiated mice, starting immediately after total-body irradiation (TBI) (within 2 h, 24 h, and 48 h post-TBI). The applied dose of RP was 50 µg/kg of body weight/day prepared with Normal Saline Solution as the vehicle. In addition to mice that received both TBI and RP (TBI + RP group), mice treated with TBI and NSS (TBI + NSS group), mice treated with RP only (0 Gy + RP group), and those treated with NSS only (0 Gy + NSS group) were prepared in this study. Furthermore, mice were also treated with Amifostine (150 mg/kg, intraperitoneal injection) 0.5 h before TBI, as an ARS protector (AMF + TBI group), which is known to prolong survival in mice and humans by scavenging radicals produced by the indirect effects of TBI.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216450/

2) Administration of ARS Protective/Mitigative Agents

The post-radiation treatment was started within 2 h after TBI. Drug combination mice with or without TBI were administered different types of medications. The four types of medications were delivered in combinations of the following two commercially available drugs based on our previous reports: recombinant human G-CSF and human TPOR agonist RP. G-CSF and RP were intraperitoneally administered once-daily for 3 or 4 times and once a week for up to 4 times, respectively. The dose of G-CSF and RP was 10 μg/kg of body weight/day, which was the same as the clinically used dose. Mice treated with TBI only and control mice alternatively received injections of normal saline solution as the vehicle used to prepare the drugs. Peripheral blood was harvested from orbital venous plexus of mice anesthetized using isoflurane, and placed at room temperature for at least 30 min to allow blood-clotting. Sera were collected by centrifugation at 3000 rpm for 10 min. The separated serum samples were stored at − 80 °C until the analysis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398212/

3) Ten-week-old WT and G6b KO mice received subcutaneous injections of either vehicle (saline) or romiplostim (100 μg/kg body weight) every 3 days for 3 weeks. The doses and administration schedules were selected according to previous studies on mice.31 Blood samples were analyzed for platelet count and volume before the onset of the experiment and on days 8 and 15. On day 21, the mice were culled and blood was drawn from the vena cava for platelet isolation.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813534/

4) Ten-week-old WT and Myh9−/− mice (5 males and 5 females in each group) received subcutaneous injections of either vehicle (saline) or romiplostim (100 μg/kg of body weight) every 3 days, during 1 month. Doses and administration schedules were selected according to previous studies in mice.11  Blood samples were analyzed for platelet count and platelet volume before the onset of the experiment and at days 8, 18, and 29. At day 33, mice were killed. Blood was drawn from the abdominal aorta for platelet isolation and electron microscopy observations. Organs (brain, lungs, pancreas, kidneys, psoas muscles, gut, and BM) were removed and immersed into 4% paraformaldehyde for histologic analysis.

https://ashpublications.org/blood/article/119/14/3333/29590/Romiplostim-administration-shows-reduced

5) All animal studies were reviewed and approved by the Italian Ministry of Health. Wild-type C57BL/6J mice were purchased from Charles River Laboratories. Mice were housed at the SPF animal facility of the University of Modena and Reggio Emilia, Modena, Italy. The Romiplostim-induced myelofibrosis (MF) mouse model was established through the subcutaneous injection of either vehicle (saline) or Romiplostim (1 mg/kg of body weight) once a week for 2 weeks in 6-to-8 weeks-old wild-type C57BL/6J mice.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169646/